Nannan Thirumavalavan, MD
Urology · Lyndhurst, OHNPI 1285923615
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Endo USA, Inc. at 42.0% of the total. 2025 is the largest year on record at $7,206, 8.5 times the $850 reported in 2019.
Across 138 payments — averaging $117.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo USA, Inc.$7K
- Endo Pharmaceuticals Inc.$4K
- Coloplast$3K
- Boston Scientific$999
- Aytu Biopharma, Inc.$258
- Tolmar, Inc.$240
- plus $552 from 13 others
What the payments were for
- Consulting fees$9,06056%
- Travel & lodging$2,44215%
- Food & beverage$4,27526%
- Education$3802%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo USA, Inc. | 16 | $6,790 |
| Endo Pharmaceuticals Inc. | 5 | $4,017 |
| Coloplast | 62 | $3,300 |
| Boston Scientific | 24 | $999 |
| Aytu Biopharma, Inc. | 1 | $258 |
| Tolmar, Inc. | 7 | $240 |
| Antares Pharma, Inc. | 5 | $114 |
| Baxter Healthcare | 1 | $77 |
| Verity Pharmaceuticals Inc. | 3 | $72 |
| Dentsply IH AB | 3 | $60 |
| Convatec Inc. | 2 | $59 |
| Olympus America Inc. | 2 | $36 |
| Bluewind Medical | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Merck | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Ambu Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,157 in reported general payments places this provider in the 85th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 30 | $2,233 |
| Testosterone Cypionate | 50 | $1,644 |
| Cabergoline | 15 | $1,386 |
| Tamsulosin Hcl | 94 | $954 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 20 | $484 |
| Finasteride | 17 | $132 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $88 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $54 |
| Anastrozole | 20 | $27 |
Paid to pharmacies, not to this prescriber.
Other urology in Lyndhurst
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.